AB-SA01

AXP000222.1 · Phage therapy

Platform
phage cocktail (fixed composition, three phages)
Originator
AmpliPhi Biosciences
Sponsor
Armata Pharmaceuticals

Names

NameTypeSource
AB-SA01preferred name, codecurator, ctgov

Virus

Role
Phage
Family
Herelleviridae
Virus
Staphylococcus phage K-related bacteriophage (three-phage cocktail)
Replication
replicating
Route
intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02757755Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy AdultsCompletedPhase 12016-052016-0812Healthy Volunteers
NCT03395769Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage TherapeuticNo longer available

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 32066959Safety of bacteriophage therapy in severe Staphylococcus aureus infection.Nature microbiology2020name in abstract: AB-SA01

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 38347019Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers.Scientific reports2024name in abstract: AB-SA01
PMID 32443619Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms.Viruses2020name in abstract: AB-SA01
PMID 32646376Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus.BMC microbiology2020name in title: AB-SA01
PMID 33077648Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model.Antimicrobial agents and chemotherapy2020name in title: AB-SA01
PMID 30669652Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections.Viruses2019name in abstract: AB-SA01
PMID 31219531Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due to Staphylococcus aureus.JAMA otolaryngology-- head & neck surgery2019name in abstract: AB-SA01

Notes

Fixed-composition product of three obligately lytic myoviruses related to Staphylococcus phage K (Lehman 2019, Viruses 11:88). Given intravenously to 13 patients with severe S. aureus infection in an open single-arm study (Petrovic Fabijan 2020, Nat Microbiol 5:465-472) and in Australian compassionate cases; US expanded-access record NCT03395769. AmpliPhi Biosciences was renamed Armata Pharmaceuticals in 2019. virus_family is given as Herelleviridae because phage K is a Kayvirus of that family; the source itself says only 'myoviruses related to phage K'.

How to cite

AB-SA01 (AXP000222.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000222.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.